2-methoxy-3-chloro-1,3-butadiene | 82578-01-6

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: 2-methoxy-3-chloro-1,3-butadiene
• 英文别名: 2-chloro-3-methoxy-buta-1,3-diene；(2-chloro-1-methylen-allyl)-methyl ether；(2-Chlor-1-methylen-allyl)-methyl-aether；3-Chlor-2-methoxy-butadien-(1.3)；2-Chlor-3-methoxy-butadien-(1,3)；2-Chloro-3-methoxybuta-1,3-diene
• CAS: 82578-01-6
• 化学式: C₅H₇ClO
• 分子量: 118.563
• InChiKey: BDOJFUMSPFUMTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methoxy-3-chloro-1,3-butadiene 在 硫酸 作用下， 生成 3-chloro-but-3-en-2-one
  参考文献：
  名称：

  Al'bitskaya,V.M. et al., Journal of general chemistry of the USSR, 1960, vol. 30, p. 2507 - 2510

  摘要：

  DOI：
• 作为产物：
  描述：

  3-Chlor-2-methoxy-buten-(3)-ol-(1) 在 氢氧化钾 作用下， 生成 2-methoxy-3-chloro-1,3-butadiene
  参考文献：
  名称：

  Al'bitskaya,V.M. et al., Journal of general chemistry of the USSR, 1960, vol. 30, p. 2507 - 2510

  摘要：

  DOI：

文献信息

• PD-L1 ANTAGONIST COMPOUND
  申请人：Adlai Nortye Biopharma Co., Ltd.

  公开号：EP4083032A1

  公开（公告）日：2022-11-02

  Provided are a compound of Formula (I) and a pharmaceutical composition thereof, as well as a method for using the compounds of Formula (I) to prevent and/or treat immune-related disorders.

  提供了化合物(I)及其制药组合物，以及使用化合物(I)预防和/或治疗免疫相关疾病的方法。
• INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF
  申请人：Nanjing Transthera Biosciences Co. Ltd.

  公开号：EP3508482A1

  公开（公告）日：2019-07-10

  Provided are an irreversible inhibitor of a fibroblast growth factor receptor (FGFR) as indicated by formula I, a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical preparation, a pharmaceutical composition and an application thereof. R1, R2, R3, R4, ring A, Ar, ring B and warhead are as defined in the specification. The compound has high-efficiency and high-selectivity inhibition of a fibroblast growth factor receptor and can be applied to treatment of abnormal FGF/FGFR-mediated diseases, in particular the treatment of cancers.

  本发明提供了一种如式 I 所示的成纤维细胞生长因子受体（FGFR）不可逆抑制剂、一种药学上可接受的盐、一种立体异构体、一种药物制剂、一种药物组合物及其应用。R1、R2、R3、R4、环 A、Ar、环 B 和弹头如说明书中所定义。该化合物对成纤维细胞生长因子受体具有高效率和高选择性的抑制作用，可应用于治疗异常的FGF/FGFR介导的疾病，特别是癌症的治疗。
• AROMATIC DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF
  申请人：Bioardis LLC

  公开号：EP3680236A1

  公开（公告）日：2020-07-15

  The present invention relates to an aromatic derivative, a preparation method thereof and medical applications thereof. Particularly, the present invention relates to a novel compound as shown in the general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same, and a preparation method thereof. The present invention further relates to use of the derivative and a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the same, in the preparation of therapeutic agents and especially FGFR4 tyrosine kinase inhibitors, and in the preparation of a drug for treating and/or preventing diseases such as tumor and inflammation. Wherein each substituent of the general formula (I) is identical with the definition in the description.

  本发明涉及一种芳香族衍生物、其制备方法及其医学应用。特别是，本发明涉及一种通式（I）所示的新型化合物及其药学上可接受的盐、含有该化合物的药物组合物及其制备方法。本发明进一步涉及该衍生物及其药学上可接受的盐或含有该衍生物的药物组合物在制备治疗剂特别是FGFR4酪氨酸激酶抑制剂中的用途，以及在制备治疗和/或预防肿瘤和炎症等疾病的药物中的用途。其中通式（I）的各取代基与描述中的定义相同。
• SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF
  申请人：Betta Pharmaceuticals Co., Ltd

  公开号：EP3845534A1

  公开（公告）日：2021-07-07

  A maleate, mesylate, benzene sulfonate, hydrochloride, phosphate, L-tartrate, L-malate, citrate, and fumarate of a compound represented by structural formula I, various crystal forms of each salt form, and a preparation method and application thereof.

  一种由结构式 I 所代表的化合物的马来酸盐、甲磺酸盐、苯磺酸盐、盐酸盐、磷酸 盐、L-酒石酸盐、L-苹果酸盐、柠檬酸盐和富马酸盐，每种盐的各种晶型，及其制备 方法和应用。
• Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
  申请人：Karyopharm Therapeutics Inc.

  公开号：US10399963B2

  公开（公告）日：2019-09-03

  The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

  本发明一般涉及取代的苯并呋喃基和取代的苯并恶唑基化合物，特别是结构式 A 所代表的化合物： 或其药学上可接受的盐，其中变量如本文所定义和描述。本发明还包括结构式A化合物或其药学上可接受的盐或组合物的合成和使用，例如用于治疗癌症（如套细胞淋巴瘤）和其它疾病和失调。